(NASDAQ: CCCC) C4 Therapeutics's forecast annual revenue growth rate of -12.21% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
C4 Therapeutics's revenue in 2025 is $39,783,000.On average, 4 Wall Street analysts forecast CCCC's revenue for 2025 to be $1,597,375,339, with the lowest CCCC revenue forecast at $514,091,281, and the highest CCCC revenue forecast at $2,577,557,113. On average, 3 Wall Street analysts forecast CCCC's revenue for 2026 to be $2,051,962,685, with the lowest CCCC revenue forecast at $1,206,836,383, and the highest CCCC revenue forecast at $2,840,283,320.
In 2027, CCCC is forecast to generate $1,786,325,187 in revenue, with the lowest revenue forecast at $764,888,298 and the highest revenue forecast at $2,485,247,905.